Option Care Health, Inc.’s stock fell over 30% on April 30, 2026, after the company reported first quarter results and cut its full year revenue guidance. The company attributed the weaker revenue outlook to a larger than expected patient census reset in its chronic inflammatory disease portfolio, including Stelara biosimilar conversions. Earlier in 2026, Option Care Health maintained its full year revenue guidance and said its related patient census assumptions were aligned with expectations.
Contact our attorneys for a no-cost case evaluation.